healthcare

January 18, 2020

The Tej Kohli Foundation has moved one step closer to a non-surgical treatment for corneal blindness as it prepares to enter into a collaboration with researchers in Montreal, Canada and Moorfields Eye Hospital, UK to develop the Foundation’s recently acquired proprietary technology into an injectable biosynthetic ‘glue-filler’.

The biosynthetic solution is a liquid form that sets as a gel at body temperature and which can then be modified to act as a tissue glue. The biosynthetic material has the potential to seal corneal perforations and cause the regeneration of corneal tissue, which would eliminate the need for corneal"...

Continue Reading >

January 17, 2020

Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).

Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration,"...

Continue Reading >

January 15, 2020

Dubai-based alternative investments firm NBK Capital Partners has announced that it has closed on its acquisition of Polymedic, a generics manufacturing company.

Headquartered in Casablanca, Morocco, the company owns a portfolio of over 200 registered products across 12 therapeutic areas.

NBK Capital Partners, alongside Foursan Capital Partners II, an institutional private equity fund based in Amman, Jordan will now own majority stake in Polymedic, a statement said.

With this transaction,"...

Continue Reading >

January 15, 2020

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) will provide an update on the progress of its business transformation and priorities today at the 38th Annual J.P. Morgan Healthcare Conference. President and Chief Executive Officer, Christophe Weber, will share details on Takeda’s portfolio and pipeline strategy, financial outlook, and ongoing sustainability efforts, including its newly established commitment to carbon neutrality"...

Continue Reading >

January 15, 2020

Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced that it has entered into a definitive agreement to sell its scil animal care business (“scil”) to Heska Corporation (“Heska”) (NASDAQ: HSKA) for a purchase price of $125 million in cash, subject to customary closing adjustments.

The transaction is expected to close in the next 60 to 90 days, subject to customary closing conditions. Covetrus expects that net cash proceeds from the transaction, after taxes and deal-related fees, will help to reduce its net debt and to improve its leverage position. The proceeds may also be used"...

Continue Reading >

January 15, 2020

The Cost Diagnosis

The medical industry is always advancing the accuracy of diagnosis for better treatment. A transition from a 64 slice CT scan to 128 and then 256 to 320 slice CT scan produces enhanced diagnosis capabilities. However, when it comes to financial health, industry perception still lies in traditional approaches to cost reduction measures. Occupancy and ARPOB is the yardstick and EBIDTA is targeted with a top-down approach.

Now, the transformation has begun with different price capping mechanisms globally, whether its DRG prices in the US and the Middle"...

Continue Reading >

January 15, 2020

Fakih IVF, one of the leading infertility centers in the GCC welcomed over 8,000 patients in the past year, demonstrating a success rate of 65%. To further extend their support to individuals battling infertility, the fertility center is running a campaign “New Year, New beginnings and a new chance at parenthood” with a hope of raising public awareness and educating individuals about the various treatment options available to better address this issue.

Through the month of January, Fakih IVF will be providing free consultation to all new and old fertility patients. Substantial discounts can also be availed on IVF-ICSI packages all"...

Continue Reading >

January 15, 2020

GNT Pharma has successfully completed a Phase III clinical trial for crisdesalazine, a new drug for treating canine cognitive dysfunction syndrome or Alzheimer’s disease. In the clinical study conducted with 48 companion dogs with severe cognitive dysfunction at 7 veterinary hospitals including Seoul National University Animal Hospital, crisdesalazine-treated group demonstrated outstanding and significant efficacy compared to the placebo group in canine cognitive dysfunction rating scale, the primary outcome measure, as well as in canine dementia scale, the secondary outcome measure. Efficacy was identified both at the 4-week and 8-week treatment in companion dogs that received 5 mg/kg or 10 mg/kg of crisdesalazine. No adverse events were found in relation with the administration of crisdesalazine. Davis research group at the University of California reported that 28% of companion dogs aged 11%12 and 68% of such dogs aged 15%16 suffer from cognitive dysfunction. As lifespan of companion dogs increases thanks to the advancement in veterinary science and healthcare, their dementia prevalence rate is on the rise. But the increase in companion dogs with dementia is emerging as a serious socio-economic problem due to the unavailability of treatment for dogs with dementia. Crisdesalazine is a multi-target drug developed to provide strong antioxidant effect and safe anti-inflammatory action to prevent amyloid plaque, neurofibrillary......

Continue Reading >

January 14, 2020

Patient Safety Movement Foundation:

WHAT:

After a routine partial hip replacement operation leaves his mother in a coma with permanent brain damage, a son’s video diary becomes a citizen’s investigation into American healthcare. Shot over the course of 10 years, using archival footage, verite scenes, undercover spy cams, courtroom testimony and interviews with family and experts, BLEED OUT goes deep inside the flawed healthcare"...

Continue Reading >

January 14, 2020

Biolog-id LLC, a world leader in connected solutions for blood and other high value health products, announced today that LiveServe Blood Center, the leading provider of blood products in Iowa, Nebraska, and South Dakota, will implement Biolog-id’s cutting-edge technology solution in its blood supply chain. The technology solution provides real-time visibility into blood product location and movement, providing actionable data to streamline inventory and improve efficiencies to maximize return on donation. Patients, donors, and staff across LifeServe’s enterprise will benefit from the actionable insights provided by a digitally visible supply chain.

“LifeServe"...

Continue Reading >